



This is a repository copy of *A systematic review of the global seasonality of infections caused by Acinetobacter species in hospitalized patients.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/150948/>

Version: Accepted Version

Article:

Kritsotakis, E. orcid.org/0000-0002-9526-3852 and Groves - Kozhageldiyeva, A. (2019) A systematic review of the global seasonality of infections caused by Acinetobacter species in hospitalized patients. *Clinical Microbiology and Infection*. ISSN 1198-743X

<https://doi.org/10.1016/j.cmi.2019.09.020>

Article available under the terms of the CC-BY-NC-ND licence
(<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



A systematic review of the global seasonality of infections caused by *Acinetobacter* species in hospitalized patients

Journal:	<i>Clinical Microbiology and Infection</i>
Manuscript ID	CLM-19-15601.R1
Article Type:	Systematic Review
Date Submitted by the Author:	n/a
Complete List of Authors:	Kritsotakis, Evangelos ; University of Crete, School of Medicine; University of Sheffield, School of Health and Related Research Groves-Kozhageldiyeva, Aigul; The University of Sheffield, School of Health and Related Research
Key Words:	<i>Acinetobacter baumannii</i> , Seasonality, Season, Climate, Healthcare associated infection, Epidemiology
Abstract:	<p>Background: <i>Acinetobacter</i> is a leading multidrug resistant pathogen in hospitals worldwide that has been seen to exhibit periodic surges during summer months. However, winter peaks and lack of seasonality have also been noted.</p> <p>Objectives: To systematically collate and examine the evidence describing seasonal patterns in the incidence of <i>Acinetobacter</i> infection in hospitalized patients.</p> <p>Data sources: MEDLINE/Ovid, EMBASE, Scopus and Web of Science.</p> <p>Study eligibility criteria: Longitudinal observational studies investigating seasonal variation in the incidence of <i>Acinetobacter</i> infection.</p> <p>Participants: Patients receiving hospital care.</p> <p>Interventions: Routine hospital care.</p> <p>Methods: Systematic review with narrative evidence synthesis structured around clinical and methodological heterogeneity and internal validity of retrieved studies, seasonal patterns and risk factors detected, and stated hypotheses of mechanisms underlying seasonality. To examine consistency in reported seasonal patterns across different conditions, monthly incidence data were extracted, standardised, weighted and presented graphically.</p> <p>Results: Twenty-five studies reporting 37006 cases of <i>Acinetobacter</i> infection or colonization during 1954 months of follow-up were reviewed. Standardised monthly incidence data pooled across studies exhibited a global seasonal pattern with an incidence peak in summer/warmer months and a trough in winter/colder months. This seasonal pattern remained consistent under different weighting schemes accounting for study size, length of follow-up and overall quality assessment rating. Seasonality persisted in different clinical settings and for different types and sources of infection. Nine studies provided consistent evidence of temperature-associated variation in <i>Acinetobacter</i> incidence, while there were controversial findings regarding other environmental variables. No study detected patient-related or clinical practice-related seasonal</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	<p>variation in Acinetobacter incidence. Conclusions: Despite substantial clinical and methodological heterogeneity in retrieved studies, a consistent global seasonal pattern in Acinetobacter infection incidence was evident in this review. This merits attention when designing or evaluating infection control interventions in hospitals. Future research should focus on elucidating driving mechanisms underlying the observed seasonality.</p>



1
2
3 1 Systematic Review
4
5
6 2
7
8

9 **A systematic review of the global seasonality of infections caused by**
10
11 ***Acinetobacter* species in hospitalized patients**
12
13
14
15

16 **Evangelos I. KRITSOTAKIS ^{1,2,*}, Aigul GROVES KOZHAGELDIYEVA ²**
17
18
19
20

21 ¹⁾ School of Medicine, University of Crete, Heraklion, Greece
22
23

24 ²⁾ School of Health and Related Research, University of Sheffield, Sheffield, United
25
26 Kingdom
27
28
29
30

31 *Correspondence:
32

33 Evangelos I. Kritsotakis
34
35

36 School of Medicine, University of Crete,
37

38 Voutes University Campus, 71003 Heraklion, Crete, Greece
39
40

41 Tel.: +30 2810 374619, Mob.: +30 6972 071823
42

43 E-mail: e.kritsotakis@uoc.gr; e.kritsotakis@sheffield.ac.uk
44
45

46
47
48 Word count, abstract: 296, main manuscript: 3574.
49

50 References: 41, Tables: 2, Figures: 2,
51
52

53 Supplementary data files: 1 (3 appendices for methods and suppl. Tables).
54
55
56
57
58
59
60

22 **ABSTRACT**

23

24 **Background:** *Acinetobacter* is a leading multidrug resistant pathogen in hospitals
25 worldwide that has been seen to exhibit periodic surges during summer months.
26 However, winter peaks and lack of seasonality have also been noted.

27 **Objectives:** To systematically collate and examine the evidence describing seasonal
28 patterns in the incidence of *Acinetobacter* infection in hospitalized patients.

29 **Data sources:** MEDLINE/Ovid, EMBASE, Scopus and Web of Science.

30 **Study eligibility criteria:** Longitudinal observational studies investigating seasonal
31 variation in the incidence of *Acinetobacter* infection.

32 **Participants:** Patients receiving hospital care.

33 **Interventions:** Routine hospital care.

34 **Methods:** Systematic review with narrative evidence synthesis structured around clinical
35 and methodological heterogeneity and internal validity of retrieved studies, seasonal
36 patterns and risk factors detected, and stated hypotheses of mechanisms underlying
37 seasonality. To examine consistency in reported seasonal patterns across different
38 conditions, monthly incidence data were extracted, standardised, weighted and
39 presented graphically.

40 **Results:** Twenty-five studies reporting 37006 cases of *Acinetobacter* infection or
41 colonization during 1954 months of follow-up were reviewed. Standardised monthly
42 incidence data pooled across studies exhibited a global seasonal pattern with an
43 incidence peak in summer/warmer months and a trough in winter/colder months. This

1
2
3 44 seasonal pattern remained consistent under different weighting schemes accounting for
4
5
6 45 study size, length of follow-up and overall quality assessment rating. Seasonality
7
8 46 persisted in different clinical settings and for different types and sources of infection.
9
10
11 47 Nine studies provided consistent evidence of temperature-associated variation in
12
13 48 *Acinetobacter* incidence, while there were controversial findings regarding other
14
15
16 49 environmental variables. No study detected patient-related or clinical practice-related
17
18 50 seasonal variation in *Acinetobacter* incidence.

19
20 51 **Conclusions:** Despite substantial clinical and methodological heterogeneity in retrieved
21
22 52 studies, a consistent global seasonal pattern in *Acinetobacter* infection incidence was
23
24 53 evident in this review. This merits attention when designing or evaluating infection
25
26 54 control interventions in hospitals. Future research should focus on elucidating driving
27
28 55 mechanisms underlying the observed seasonality.
29

30
31
32 56
33
34 57 **Key words:**

35
36
37 58 *Acinetobacter baumannii*; Seasonality; Season; Climate; Healthcare associated infection;
38
39 59 Epidemiology.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

60 Introduction

61

62 *Acinetobacter* species, particularly *Acinetobacter baumannii* is a leading
63 multidrug resistant microorganism in hospitals worldwide causing severe nosocomial
64 infections such as bloodstream infections and ventilator-associated pneumonia [1–3].

65 The abilities of the organism to survive in inanimate environments for long times,
66 rapidly develop antibiotic resistance and spread clonally potentiate the persistence and
67 transmission of the species in healthcare settings [3,4]. *Acinetobacter* is also one of the
68 first nosocomial pathogens that has been reported to exhibit periodic peaks in its
69 incidence during the summer or warmer months [5]. However, opposite seasonal
70 occurrence with peaks during winter and lack of seasonality have also been reported
71 [6,7]. The reasons for this variability remain poorly understood [8].

72 This study aims to systematically collate and evaluate the existing evidence
73 describing seasonal patterns in the incidence of *Acinetobacter* infection in hospitalized
74 patients. Moreover, factors found to be associated with seasonal variation and
75 hypotheses of mechanisms underlying seasonality were recorded. Methods used to
76 assess seasonality, internal validity and clinical heterogeneity of retrieved studies were
77 examined.

78

79 Methods

80

1
2
3
4 81 This systematic review is PROSPERO-registered (registration number:
5
6 82 CRD42018114547) and complies with the Preferred Reporting Items for Systematic
7
8 83 Reviews and Meta-Analyses (PRISMA) statement [9].
9

10
11 84

12 13 85 **Search strategy**

14
15 86 MEDLINE/Ovid, EMBASE, Scopus and Web of Science were searched up until 23
16
17 87 October 2018 for longitudinal observational studies investigating seasonal variation in
18
19 88 the incidence of infections caused by *Acinetobacter* spp. in hospital settings. The search
20
21 89 was restricted to research articles written in English and published in peer-reviewed
22
23 90 journals. Different combinations of the keywords “*Acinetobacter*”, “*Acinetobacter*
24
25 91 *baumannii*”, “*Acinetobacter infections*”, “seasonal pattern” and “season*” were used to
26
27 92 retrieve the articles (detailed in Supplementary [Appendix A](#)). Manual checking of
28
29 93 reference lists and citation tracking of included papers in Scopus and Web of Science
30
31 94 were performed.
32
33
34
35
36
37
38
39

40 96 **Screening and eligibility**

41
42 97 Duplicate records were removed using the Mendeley reference managing software.
43
44 98 A two-step screening process for eligibility was undertaken. First, one author (AGK)
45
46 99 excluded ineligible studies by screening titles and abstracts. Then, both authors
47
48 100 reviewed independently the full texts of potentially eligible studies for inclusion in the
49
50 101 review. Disagreements were resolved through discussion and consensus. Eligibility was
51
52
53
54
55
56
57
58
59
60

1
2
3
4 102 assessed by applying the PICOS (population, intervention, comparators/controls,
5
6 103 outcomes and study design) question format [9], as follows:
7
8 104 ▪ Population: Patients receiving hospital care.
9
10 105 ▪ Intervention: Experimental studies and outbreak reports were excluded from
11
12 the review because of possible interference that interventions might have on
13 106
14
15 107 transmission dynamics of *Acinetobacter* spp in routine care settings.
16
17
18 108 ▪ Comparators/controls: Presence of a control group was not a requirement
19
20 109 for study inclusion.
21
22
23 110 ▪ Outcomes: The outcome of interest was the incidence (expressed as count,
24
25 111 proportion or rate) of hospital-acquired or community-acquired infection, at
26
27 any site, that was caused by *Acinetobacter* species in hospitalized patients.
28 112
29 Studies not distinguishing colonization from infection were included.
30 113
31
32 114 ▪ Study design: Observational longitudinal studies reporting the incidence of
33
34 *Acinetobacter* spp. infections, with at least 12 consecutive months of follow-
35 115
36 up to cover all seasons, were included.
37 116
38
39 117 Studies that did not fulfil the eligibility criteria were excluded and reasons stated
40
41
42 118 (Supplementary [Appendix B](#)).
43
44
45 119

120 **Data extraction**

121 Information extracted from retrieved studies included: identification data (first
122 122 author, title and year of publication); study design, length of follow-up; geographical
123 123 location and data source; type or specialty of patients; total number of infections;

1
2
3 124 source of infection (community- or hospital- acquired); type/site of infection; and
4
5 125 member of the *Acinetobacter* species. Additionally, factors found to be associated with
6
7 126 and factors found not to be associated with seasonal variation, and hypotheses on
8
9 127 mechanisms of seasonality (argued for or against by the authors) were recorded. Where
10
11 128 available, monthly or quarterly incidence counts, proportions or rates of *Acinetobacter*
12
13 129 infection were extracted. Data presented in graphical format were retrieved using Plot
14
15 130 Digitizer version 2.6.6 (<http://plotdigitizer.sourceforge.net/>). Data were summarized in
16
17 131 a Google spreadsheet by one author (AGK) and crosschecked by the other author (EIK).
18
19
20
21
22
23
24

25 133 ***Evidence synthesis***

26
27 134 Findings were summarised in a narrative synthesis structured around clinical
28
29 135 heterogeneity, methodological characteristics and quality assessment of retrieved
30
31 136 studies, seasonal patterns detected, risk factors and hypotheses of mechanisms
32
33 137 underlying seasonality. To describe and assess consistency in reported seasonal
34
35 138 patterns, monthly infection incidence data were standardised using z-scores on a study-
36
37 139 by-study basis to bring different units of measurement into one common scale across
38
39 140 studies. Data from studies in the southern hemisphere were adjusted by six months. The
40
41 141 average of standardised monthly incidence data across all studies was then plotted.
42
43 142 Different weighting schemes were used to account for length of follow-up, study size
44
45 143 and overall quality rating. Stratified graphs of standardized data were used to examine
46
47 144 consistency in seasonality for different types and sources of infection and between
48
49 145 different clinical settings.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 146
45
6 147 **Quality appraisal**
7

8 148 Internal validity of each study was assessed by one author (EIK) based on the
9
10 149 Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [10].
11
12 150 Appendix C details how this assessment was carried out. We also assessed
13
14 151 methodological heterogeneity in relation to whether studies were performed with the
15
16 152 specific objective of assessing seasonality, what their scale and coverage were, and
17
18 153 which statistical methods were used to assess seasonality. For the latter, the statistical
19
20 154 method was classified into one of four distinct types [11]: (a) graphical inspection of
21
22 155 incidence data over time; (b) direct comparison of incidence between discrete calendar
23
24 156 periods; (c) geometrical model assuming a sinusoidal cyclic pattern, and (d) generalised
25
26 157 linear and/or time series regression model.
27
28
29
30
31
32
33
34

35 159 **Results**
36
37
38
39
4041 161 ***Setting and clinical heterogeneity of retrieved studies***
42

43 162 The search identified 294 non-duplicate publications, of which 25 met the
44
45 163 eligibility criteria and were reviewed (Figure 1). Main characteristics of the studies are
46
47 164 summarised in Table I. The studies were published from 1979 to 2018 and 15 (60%)
48
49 165 appeared over the last 10 years. Most studies (n=18; 72%) were conducted in countries
50
51 166 in the Northern Hemisphere (8 in North America, 6 in Europe and 4 in Asia), and only a
52
53 167 quarter (n=6; 24%) were in the Southern Hemisphere (5 in Brazil and 1 in Australia). One
54
55
56
57
58
59
60

1
2
3 168 study was multi-national and included countries in both North and South America. Most
4
5
6 169 (n=19; 76%) were performed at a single institution, while 6 (24%) were multi-centre
7
8 170 studies. The majority of studies (n=20; 80%) were conducted hospital-wide, while a fifth
9
10 171 of the investigations (n=5; 20%) were restricted in ICUs. There was no age restriction in
11
12 172 11 (44%) studies, 3 (12%) studies examined only adult patients and 11 (44%) studies did
13
14
15 173 not report patient demographics.

16
17
18 174 Overall, 37006 cases of *Acinetobacter* infection during 1954 months of follow-up
19
20 175 were reported. Colonization was not distinguished from infection in 11 (44%) reports,
21
22 176 while 13 (52%) studies reported infection only and 1 (4%) study examined colonization
23
24
25 177 only. Hospital-acquired cases were not distinguished from community-onset cases in 12
26
27 178 (48%) occasions, while 10 (40%) studies examined hospital-acquired cases only, 1 (4%)
28
29 179 included community-onset cases only and 2 (8%) studies contrasted between hospital-
30
31 180 acquired and community-onset cases. In relation to infection type, 13 studies (52%)
32
33 181 reported all types of infections combined, while 11 (44%) studies looked at bacteraemia
34
35 182 only and 1 (4%) investigated pneumonia only.
36
37
38
39
40
41
42

43 184 **Methodological characteristics and quality assessment**

44
45 185 Retrieved studies were case-series (16/25; 64%) or cohort studies (9/25; 36%)
46
47 186 that examined longitudinally the incidence of *Acinetobacter* infection based on routine
48
49 187 clinical cultures. Most studies collected data retrospectively (n=15; 60%). There were 15
50
51 188 (60%) studies performed with the specific objective of assessing seasonality and the
52
53
54 189 remaining 10 studies (40%) assessed seasonal occurrence as a secondary objective. To
55
56
57
58
59
60

1
2
3 190 assess seasonality, the authors relied mostly on graphical inspections of disease
4
5
6 191 incidence over time (n=9; 36%) or direct comparison of incidence data between discrete
7
8 192 calendar periods (n=11; 44%). One study used a geometrical model and 4 (16%) studies
9
10 193 utilized a generalised linear model. Using the Quality Assessment Tool for Observational
11
12 194 Studies, the average quality score of included studies was 79% (SD 13.8%; range 45%-
13
14 195 100%) and only 4 studies (16%) obtained a rating below 70% (Table C2, supplementary
15
16 196 Appendix C).
17
18
19
20
21
22

23 198 ***Global seasonal patterns***

24
25 199 Seasonal variation in *Acinetobacter* infections was reported in 18/25 (72%) studies;
26
27 200 whereas 4 (16%) concluded absence of seasonality and 3 (12%) studies were
28
29 201 inconclusive. Seasonality was concluded in 13 of the 15 (87%) studies that assessed it as
30
31 202 a primary objective and in 5 of the 10 studies (50%) that looked at seasonality as a
32
33 203 secondary objective.
34
35
36

37 204 All but four studies [8,12–14] reported monthly incidence data in tables and/or
38
39 205 graphs and we extracted 27 series of monthly incidence data from 21/25 (84%) studies
40
41 206 (Table II). Extracted monthly incidence of *Acinetobacter* infections peaked in the
42
43 207 summer in 12/21 (57.1%) studies, spring in 2/21 (9.5%) studies, autumn in 2/21 (9.5%)
44
45 208 studies, and in the winter in 1/21 (4.8%) study. Differential seasonal variation was noted
46
47 209 in 4/21 (19%) studies in relation to source of infection (summer peak for community-
48
49 210 onset infections vs. winter peak for hospital-acquired infections) [15], antimicrobial
50
51 211 resistance (summer peak for non-MDR isolates vs. winter peak for MDR) [7], clinical
52
53
54
55
56
57
58
59
60

1
2
3 212 setting (summer peak in wards vs. autumn peak in ICUs) [16], or location (winter peak in
4
5
6 213 Latin America vs autumn peak in Canada and USA) [17].
7

8 214 When monthly incidence data were standardised and pooled across studies, a
9
10 215 clear seasonal pattern in *Acinetobacter* incidence with a peak in summer/warmer
11
12
13 216 months and a trough in winter/colder months was evident. This remained consistent
14
15 217 under different weights to account for length of follow-up, number of infections and
16
17
18 218 quality rating of the studies (Figure 2, panel a). The same seasonal pattern persisted
19
20 219 when we examined pooled standardised data in relation to seasonality objective
21
22
23 220 (primary v. secondary), clinical setting (hospital-wide v. ICU), continent where the
24
25 221 studies were performed, infection origin (hospital-acquired v. community-onset),
26
27
28 222 infection type (any infection v. bacteraemia only), infection status (colonization or
29
30 223 infection v. infection only), and *Acinetobacter* group (Figure 2, panels b-h).
31

32
33 224

34 35 225 **Factors associated with seasonal variation**

36
37 226 Ten (40%) studies examined the relation to weather parameters (ambient
38
39
40 227 temperature, relative humidity and precipitation or rainfall) [7,8,12,13,15,18–22]. Three
41
42
43 228 of these additionally looked at or controlled for patient-related risk factors and/or
44
45 229 clinical practice indicators [12,21,22]. To this end, most studies (7/10; 70%) relied on
46
47
48 230 multivariable generalized linear models (Poisson [8,13,19,20], negative binomial [22] or
49
50 231 logistic [12,21] regression), while the remaining 3 studies used bivariate correlation
51
52 232 coefficients [7,15,18].
53
54
55
56
57
58
59
60

1
2
3 233 All nine studies that examined ambient temperature found a positive association
4
5
6 234 with *Acinetobacter* incidence [7,8,12,13,15,19–22]. Of note, one study was conducted
7
8 235 exclusively in ICUs [22] and another found that temperature-associated variation in
9
10 236 *Acinetobacter* infections persisted in the subgroup of patients admitted to ICUs [21],
11
12
13 237 which were units with climate control. In contrast, of the 5 studies examining relative
14
15 238 humidity, 4 did not find an association with *Acinetobacter* incidence [8,13,19,21] and 1
16
17
18 239 noted a negative association [12]. Results were more variable regarding precipitation,
19
20 240 which was examined in 3 studies and was seen to exhibit negative [8], positive [18] or
21
22
23 241 no correlation [19] with *Acinetobacter* incidence.

24
25 242 All three studies that examined patient-related and/or clinical practice-related
26
27 243 risk factors noted lack of association with *Acinetobacter* incidence. Factors studied were
28
29
30 244 patient age and sex [12], ICU admission [12,21], Charlson comorbidity index [21], length
31
32 245 of stay or time at risk [12,22], device utilization indices [22], size and type of ICU or
33
34
35 246 hospital [22], and number of pathogens isolated in the previous month [22]. In addition,
36
37 247 *Acinetobacter* occurrence was measured as an incidence density rate in 4 studies, using
38
39
40 248 patient-days [22–24] or device-days [25] in the denominator thereby controlling for
41
42
43 249 fluctuations in admissions, length of stay and intensity of device use. Moreover, one
44
45 250 study examined the molecular heterogeneity of isolates and established that the
46
47 251 seasonal increase in *A. baumannii* was not due to clonal dissemination of a single strain
48
49
50 252 [26].

51
52 253

53
54 254 **Hypotheses of underlying mechanisms**

1
2
3
4 255 Reviewed studies considered several explanatory hypotheses of mechanisms
5
6 256 underlying the seasonality of *Acinetobacter* infections. Several authors raised the
7
8 257 possibility of community-associated origins related to increased bacterial growth
9
10 258 [15,19,27] and/or survival in environmental reservoirs [8,12,13,21] outside the hospital
11
12
13 259 setting in higher temperatures. These, in turn, was hypothesized to lead to increased
14
15 260 colonization of humans and increased inflow of *Acinetobacter* carried by patients and
16
17 261 healthcare workers into hospitals during warmer months [8,12,13,19].

18
19
20 262 The possibility that higher temperatures may modulate the virulence of
21
22 263 *Acinetobacter* via regulating the lipid A moiety of lipopolysaccharide in its outer
23
24
25 264 membrane, thereby contributing to increases in infection occurrence in warmer periods,
26
27 265 was also considered [19]. Others suggested that increased ambient temperature may
28
29 266 promote a biofilm "bloom" of *Acinetobacter* species in hospital tap water which,
30
31 267 similarly to *Pseudomonas aeruginosa*, may be related to increased isolation from
32
33 268 standing tap water in patient rooms and higher fecal carriage of healthy adults during
34
35 269 the summer months [20,25]. Another suggestion was that the photoperiod (dark-light
36
37 270 cycles) and not temperature per se might contribute to seasonality because host
38
39 271 susceptibility may depend on the photoperiod and mediated by the length of daily
40
41 272 melatonin pulse and a range of other physiologic parameters [22].

42
43 273 Stated hypotheses also acknowledged a potential role of non-weather-related
44
45 274 seasonal factors including understaffing due to summer vacations that may lead to
46
47 275 higher workload and/or lower adherence to infection control measures [8,27], intern
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 276 inexperience with infection control methods and obtaining clinical cultures at different
4
5
6 277 frequencies in summer [19].
7

8 278
9

10 279 **Discussion**

11
12
13
14 280

15
16 281 Our evidence synthesis suggests that the incidence of *Acinetobacter* infection in
17
18 282 hospitalised patients is characterised by a global seasonal pattern with a peak in
19
20
21 283 summer/warmer months and a trough in winter/colder months. In our descriptive
22
23
24 284 graphical assessment, the seasonal pattern remained robust when we gave more weight
25
26 285 to studies with greater follow-up times (as repetition over several years is more likely to
27
28 286 reflect true seasonality), those with larger effective sample size (which avoid potential
29
30
31 287 masking of temporal patterns because of recording few infections) or those with higher
32
33 288 quality ratings. Moreover, the same seasonal pattern was seen irrespective of whether
34
35
36 289 the studies addressed seasonality as primary or secondary objective, whether infection
37
38 290 onset was hospital-associated or community-associated, whether the investigation was
39
40
41 291 performed in ICUs or hospital-wide, whether reporting was restricted to infections or
42
43 292 included colonizations, and whether studies reported *A. baumannii* or other members of
44
45
46 293 the species. Therefore, the phenomenon of seasonality in the occurrence of
47
48 294 *Acinetobacter* infection in hospitalized patients appears to be a robust finding that
49
50
51 295 merits attention when designing or evaluating strategies for infection prevention and
52
53 296 control in hospitals.
54
55
56
57
58
59
60

1
2
3 297 This global seasonal pattern does not seem to relate simply to seasonal variation
4
5
6 298 in admission times or hospital crowding or susceptibility of the patient population, and
7
8 299 our results show that the mechanisms underlying seasonality remain largely obscure.
9
10 300 We identified consistent evidence of temperature-associated variation in *Acinetobacter*
11
12 301 incidence in all studies that examined this possibility by incorporating measurements of
13
14 302 ambient temperature in their analysis [7,8,12,13,15,19–22]; whereas we noted
15
16 303 inconsistent findings regarding other weather parameters. Consequently, temperature-
17
18 304 driven considerations pointing mostly to community-associated origins of the seasonal
19
20 305 surges in *Acinetobacter* infections within hospitals were most dominant in forming
21
22 306 hypotheses on mechanisms for seasonality in reviewed studies.
23
24
25
26
27

28 307 The most common causal hypothesis proposed that higher temperature
29
30 308 promotes bacterial growth, environmental reservoirs, virulence and/or biofilm
31
32 309 formation in *Acinetobacter* outside healthcare settings, which somehow increase the
33
34 310 inflow of carriers into hospitals. This hypothesis is supported by increasing evidence that
35
36 311 traits such as antibiotic resistance, biofilm formation and twitching motility can be
37
38 312 thermoregulated in *Acinetobacter* [28,29]. The organism also adapts rapidly to
39
40 313 temperature shift (from room temperature to 37°C) and to availability of nutrients
41
42 314 (from starvation to food availability), conditions easily found in new patients [30]. The
43
44 315 community-associated (rather than healthcare-associated) origins of the increased
45
46 316 incidence of *Acinetobacter* during summer or warmer months is supported by our
47
48 317 finding of a persisting seasonal pattern when we looked at data from studies performed
49
50 318 solely in ICUs, where climate conditions are largely artificial and stable. An investigation
51
52
53
54
55
56
57
58
59
60

1
2
3 319 in 73 German ICUs revealed temperature-associated variation in *Acinetobacter*
4
5
6 320 incidence despite that 83% of the units were air-conditioned during the entire study
7
8 321 period [22]. The hypothesis of community-associated origins may be supported further
9
10 322 by observations of polyclonal increase in *Acinetobacter* in summer/warmer months;
11
12
13 323 however, we identified only one study that provided relevant evidence by examining the
14
15 324 molecular heterogeneity of the isolates [26].

17
18 325 On the other hand, strictly community origins of incidence peaks in
19
20 326 *Acinetobacter* infections are difficult to justify in light of our findings. We were able to
21
22 327 extract 27 series of monthly data from reviewed studies, which produced a similar
23
24
25 328 seasonal pattern irrespective of whether the origin of infections was associated with the
26
27 329 community (n=3), the hospital (n=11) or a mixture of the two (n=13). Moreover,
28
29
30 330 *Acinetobacter* is characterised by multidrug resistance, which is highly clonal in nature
31
32 331 and a proxy of nosocomial origin. Only two studies attempted to examine seasonal
33
34 332 variation in relation to the antimicrobial susceptibility of *Acinetobacter* isolates and
35
36 333 produced conflicting results. In a single-centre study in the USA, significantly more non-
37
38 334 MDR *A. baumannii* cases were identified in warm months than in cold months, but a
39
40
41 335 similar pattern was not observed for MDR cases [7]. In contrast, a single-centre in Brazil
42
43 336 noted a stronger association of temperature with imipenem-resistant than with
44
45 337 imipenem-susceptible strains of *A. baumannii* [8]. The possibility of differential variation
46
47 338 depending on antimicrobial susceptibility should be addressed in future studies. Future
48
49 339 research should also consider competing explanations based on non-weather-related
50
51 340 seasonal factors such as understaffing associated with summer vacations, changes in
52
53
54
55
56
57
58
59
60

1
2
3 341 adherence to isolation precautions, or obtaining clinical cultures at different frequencies
4
5
6 342 in summer. Empirical evidence for such associations is limited but appears to suggest
7
8 343 that understaffing and bed occupancy rates correlate with the spread of hospital-
9
10 344 acquired infections [31]. Therefore, different mechanisms might explain the seasonal
11
12 345 flow of *Acinetobacter* inside and outside the hospital and future explanatory studies
13
14
15 346 should emphasize on clearly distinguishing between hospital-acquired and community-
16
17
18 347 acquired cases.

19
20 348 We did not identify different seasonality between studies that included all types
21
22 349 of infections combined and those that included *Acinetobacter* bacteraemia only.
23
24
25 350 However, the current literature has not examined other infection types and we cannot
26
27
28 351 exclude the possibility that seasonal variation might depend on the site of infection. It is
29
30 352 not unreasonable, for example, to expect that pneumonias might peak during the colder
31
32 353 months. Similarly, we did not identify differences between studies that examined
33
34
35 354 colonization in conjunction with infection and those that examined infection only.
36
37
38 355 However, only one study assessed colonization only and we cannot exclude the
39
40 356 possibility of a difference in seasonal variation between *Acinetobacter* infections and
41
42
43 357 colonizations. This would provide further insight into potential mechanisms underlying
44
45 358 seasonality [32]. A time lag between seasonal peaks in colonization compared to
46
47
48 359 infection would support the role of seasonal factors on *Acinetobacter* transmission and
49
50 360 colonization. Seasonality in infection but not colonization would indicate that seasonal
51
52 361 factors somehow affect host susceptibility to progression from colonization to infection
53
54
55 362 [32]. These scenarios require validation in future studies.
56
57
58
59
60

1
2
3 363 In common with other reviews of the seasonality of infectious diseases
4
5
6 364 [11,32,33], we identified that the bulk of the literature on the topic lacks robust
7
8 365 statistical methodology. Graphical inspection or direct numerical comparison of
9
10 366 *Acinetobacter* incidence over discrete calendar seasons were dominant approaches in
11
12
13 367 assessing seasonality. However, aggregation of cases by calendar season may result in
14
15 368 loss of information if infection occurrences have other periodicity (e.g. biannual) [11,33].
16
17
18 369 Direct comparison between discrete time intervals is limited by the inability to compare
19
20 370 more than two intervals at once [11]. The geometrical model is outperformed by
21
22
23 371 Poisson regression when estimating the magnitude of seasonal variation [34]. Therefore,
24
25 372 time-series regression models should be preferred when studying the seasonality of
26
27
28 373 infectious diseases [11,33]. However, appropriate regression modelling was utilized in
29
30 374 only 4 (16%) of reviewed studies and this should be kept in mind when interpreting
31
32
33 375 results from individual studies.

34
35 376 The potential for publication bias should be considered because 40% of the
36
37 377 reviewed studies were not performed with the primary objective of assessing
38
39
40 378 seasonality. We should thus assess the possibility of a bias towards reporting results
41
42
43 379 whenever seasonality was observed and not reporting them when no such seasonal
44
45 380 variation was seen [32]. Our findings oppose this possibility because seasonality was
46
47
48 381 reported in the great majority (13/15; 87%) of studies that assessed it as a primary
49
50 382 objective, compared with half (5/10; 50%) of those that included seasonality as a non-
51
52 383 specific objective. Moreover, the seasonal pattern in *Acinetobacter* incidence remained
53
54
55 384 consistent when we examined pooled standardised data in relation to seasonality
56
57
58
59
60

1
2
3 385 objective (primary v. secondary) and persisted under different data weights accounting
4
5
6 386 for study size and overall quality rating.
7

8 387 Individual studies reported *Acinetobacter* incidence with different metrics and
9
10 388 we utilized z-scores to standardize the data across studies. This enabled us to examine
11
12 389 consistency or robustness of the same seasonal pattern under different conditions by
13
14 390 graphically comparing standardized data pooled across distinct subgroups. However,
15
16 391 standardization masks the amplitude between the peak and the trough in disease
17
18 392 incidence. Moreover, we did not attempt to estimate the magnitude or intensity of the
19
20 393 seasonal effect that may vary substantially in different settings. Therefore, our analysis
21
22 394 supports global consistency in the seasonal pattern of *Acinetobacter*, not a global
23
24 395 magnitude of the seasonal effect. Another important consideration in interpreting our
25
26 396 findings is that most data come from North America and Europe – regions with
27
28 397 temperate climate and similar income level and health care infrastructure. Fewer
29
30 398 studies were from tropical or sub-tropical zones in the southern hemisphere, almost all
31
32 399 South American studies were done in Brazil and there was no data from Africa, which is
33
34 400 a considerable gap in available information from those regions.
35
36
37
38
39
40
41
42
43

401

402 **Conclusions**

403

404 This systematic assessment of the literature suggests that the occurrence of
405 *Acinetobacter* infections in hospitalised patients is characterised by a robust global
406 seasonal pattern with an incidence peak in summer/warmer months and an incidence

1
2
3 407 trough in winter/colder months. This merits attention when designing or evaluating
4
5
6 408 strategies for infection prevention and control in hospitals. We hope that our evaluation
7
8 409 of the current evidence will prompt future investigations into the seasonality of
9
10 410 *Acinetobacter* infections to elucidate the mechanisms underlying the phenomenon.
11
12

13 411
14

15 16 412 **Transparency declaration**

17
18 413 The authors report no conflicts of interest. No external funding was received for this
19
20
21 414 work.
22

23 415
24

25 26 416 **Supplementary data**

27
28
29 417 Appendix A. Search strategy

30
31 418 Appendix B. Excluded studies with reasons

32
33
34 419 Appendix C. Critical appraisal of the quality of reviewed studies
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

420 **References**

421

- 422 [1] Antunes LCS, Visca P, Towner KJ. *Acinetobacter baumannii*: Evolution of a global
423 pathogen. *Pathog Dis* 2014;71:292–301. doi:10.1111/2049-632X.12125.
- 424 [2] Tsioutis C, Kritsotakis EI, Karageorgos SA, Stratakou S, Psarologakis C, Kokkini S, et
425 al. Clinical epidemiology, treatment and prognostic factors of extensively drug-
426 resistant *Acinetobacter baumannii* ventilator-associated pneumonia in critically ill
427 patients. *Int J Antimicrob Agents* 2016;48:492–7.
428 doi:10.1016/j.ijantimicag.2016.07.007.
- 429 [3] European Centre for Disease Prevention and Control. Carbapenem-resistant
430 *Acinetobacter baumannii* in healthcare settings. Stockholm: 2016.
- 431 [4] Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a
432 successful pathogen. *Clin Microbiol Rev* 2008;21:538–82.
433 doi:10.1128/CMR.00058-07.
- 434 [5] Richet H. Seasonality in Gram-negative and healthcare-associated infections. *Clin*
435 *Microbiol Infect* 2012;18:934–40. doi:10.1111/j.1469-0691.2012.03954.x.
- 436 [6] Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H.
437 Nosocomial bloodstream infections caused by *Acinetobacter* species in United
438 States hospitals: clinical features, molecular epidemiology, and antimicrobial
439 susceptibility. *Clin Infect Dis* 2000;31:690–7. doi:10.1086/314040.
- 440 [7] Fukuta Y, Clarke LG, Shields RK, Wagener MM, Pasculle AW, Doi Y. Lack of
441 seasonality in the occurrence of multidrug-resistant *Acinetobacter baumannii*

- 1
2
3 442 complex. *Infect Control Hosp Epidemiol* 2012;33:1051–2. doi:10.1086/667741.
- 4
5
6 443 [8] da Silveira M, da Silva LP, de Oliveira Emídio ZP, Fortaleza CMCB. Weather,
7
8 444 climate control, and imipenem-resistance in *Acinetobacter baumannii*: an
9
10 445 ecological approach. *Infect Control Hosp Epidemiol* 2018;39:1133–5.
11
12 446 doi:10.1017/ice.2018.171.
- 13
14
15 447 [9] Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting
16
17 448 items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin*
18
19 449 *Epidemiol* 2009;62:1006–12. doi:10.1016/j.jclinepi.2009.06.005.
- 20
21
22 450 [10] U.S. Department of Health & Human Services. Quality Assessment Tool for
23
24 451 Observational Cohort and Cross-Sectional Studies n.d.
25
26 452 <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>
27
28 453 (accessed January 28, 2019).
- 29
30
31 454 [11] Christiansen CF, Pedersen L, Sørensen HT, Rothman KJ. Methods to assess
32
33 455 seasonal effects in epidemiological studies of infectious diseases--exemplified by
34
35 456 application to the occurrence of meningococcal disease. *Clin Microbiol Infect*
36
37 457 2012;18:963–9. doi:10.1111/j.1469-0691.2012.03966.x.
- 38
39
40 458 [12] Caldeira SM, Cunha AR da, Akazawa RT, Moreira RG, Souza L do R de, Fortaleza
41
42 459 CMCB. Weather parameters and nosocomial bloodstream infection: a case-
43
44 460 referent study. *Rev Saude Publica* 2015;49:19. doi:10.1590/S0034-
45
46 461 8910.2015049005438.
- 47
48
49 462 [13] Fortaleza CMCB, Caldeira SM, Moreira RG, Akazawa RT, Corrente JE, de Souza L
50
51 463 do R, et al. Tropical healthcare epidemiology: weather determinants of the

- 1
2
3 464 etiology of bloodstream infections in a Brazilian hospital. *Infect Control Hosp*
4
5
6 465 *Epidemiol* 2014;35:85–8. doi:10.1086/674392.
- 7
8 466 [14] Kolonitsiou F, Papadimitriou-Olivgeris M, Spiliopoulou A, Stamouli V, Papakostas
9
10 467 V, Apostolopoulou E, et al. Trends of Bloodstream Infections in a University Greek
11
12 468 Hospital during a Three-Year Period: Incidence of Multidrug-Resistant Bacteria
13
14
15 469 and Seasonality in Gram-negative Predominance. *Polish J Microbiol* 2017;66:171–
16
17 470 80.
- 18
19
20 471 [15] Kim YA, Kim JJ, Won DJ, Lee K. Seasonal and Temperature-Associated Increase in
21
22 472 Community-Onset *Acinetobacter baumannii* Complex Colonization or Infection.
23
24 473 *Ann Lab Med* 2018;38:266–70. doi:10.3343/alm.2018.38.3.266.
- 25
26
27 474 [16] Siau H, Yuen KY, Wong SSY, Ho PL, Luk WK. The epidemiology of acinetobacter
28
29 475 infections in Hong Kong. *J Med Microbiol* 1996;44:340–7. doi:10.1099/00222615-
30
31 476 44-5-340.
- 32
33
34 477 [17] Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging
35
36 478 importance of multidrug-resistant *Acinetobacter* species and *Stenotrophomonas*
37
38 479 *maltophilia* as pathogens in seriously ill patients: geographic patterns,
39
40 480 epidemiological features, and trends in the SENTRY Antimicrobial Surveillance
41
42 481 Program (1997-1999). *Clin Infect Dis* 2001;32 Suppl 2:S104-13.
43
44 482 doi:10.1086/320183.
- 45
46
47 483 [18] Davis JS, McMillan M, Swaminathan A, Kelly JA, Piera KE, Baird RW, et al. A 16-
48
49 484 year prospective study of community-onset bacteremic *Acinetobacter*
50
51 485 pneumonia: low mortality with appropriate initial empirical antibiotic protocols.
52
53
54
55
56
57
58
59
60

- 1
2
3 486 Chest 2014;146:1038–45. doi:10.1378/chest.13-3065.
4
5
6 487 [19] Eber MR, Shardell M, Schweizer ML, Laxminarayan R, Perencevich EN. Seasonal
7
8 488 and temperature-associated increases in gram-negative bacterial bloodstream
9
10 489 infections among hospitalized patients. PLoS One 2011;6:e25298.
11
12
13 490 doi:10.1371/journal.pone.0025298.
14
15 491 [20] Perencevich EN, McGregor JC, Shardell M, Furuno JP, Harris AD, Morris JG, et al.
16
17 492 Summer Peaks in the Incidences of Gram-Negative Bacterial Infection Among
18
19 493 Hospitalized Patients. Infect Control Hosp Epidemiol 2008;29:1124–31.
20
21
22 494 doi:10.1086/592698.
23
24
25 495 [21] Rodrigues FS, Clemente de Luca FA, Ribeiro da Cunha A, Fortaleza CMCB. Season,
26
27 496 weather and predictors of healthcare-associated Gram-negative bloodstream
28
29 497 infections: a case-only study. J Hosp Infect 2019;101:134–41.
30
31
32 498 doi:10.1016/j.jhin.2018.06.015.
33
34
35 499 [22] Schwab F, Gastmeier P, Meyer E. The warmer the weather, the more gram-
36
37 500 negative bacteria - impact of temperature on clinical isolates in intensive care
38
39 501 units. PLoS One 2014;9:e91105. doi:10.1371/journal.pone.0091105.
40
41
42 502 [23] Lastoria LC, Caldeira SM, Moreira RG, Akazawa RT, Maion JC, Fortaleza CMCB.
43
44 503 Ecological competition and the incidence of *Acinetobacter baumannii*
45
46 504 bloodstream infections in a teaching hospital in Southeastern Brazil. Rev Soc Bras
47
48 505 Med Trop 2014;47:583–8. doi:10.1590/0037-8682-0161-2014.
49
50
51 506 [24] Papadimitriou-Olivgeris M, Fligou F, Spiliopoulou A, Koutsileou K, Kolonitsiou F,
52
53 507 Spyropoulou A, et al. Risk factors and predictors of carbapenem-resistant
54
55
56
57
58
59
60

- 1
2
3 508 *Pseudomonas aeruginosa* and *Acinetobacter baumannii* mortality in critically ill
4
5 509 bacteraemic patients over a 6-year period (2010-15): antibiotics do matter. *J Med*
6
7 510 *Microbiol* 2017;66:1092–101. doi:10.1099/jmm.0.000538.
8
9
10 511 [25] McDonald LC, Banerjee SN, Jarvis WR. Seasonal variation of *Acinetobacter*
11
12 512 infections: 1987-1996. Nosocomial Infections Surveillance System. *Clin Infect Dis*
13
14 513 1999;29:1133–7. doi:10.1086/313441.
15
16
17 514 [26] Christie C, Mazon D, Hierholzer W, Patterson JE. Molecular heterogeneity of
18
19 515 *Acinetobacter baumannii* isolates during seasonal increase in prevalence. *Infect*
20
21 516 *Control Hosp Epidemiol* 1995;16:590–4.
22
23
24 517 [27] Fillaux J, Dubouix A, Conil J-M, Laguerre J, Marty N. Retrospective analysis of
25
26 518 multidrug-resistant *Acinetobacter baumannii* strains isolated during a 4-year
27
28 519 period in a university hospital. *Infect Control Hosp Epidemiol* 2006;27:647–53.
29
30 520 doi:10.1086/507082.
31
32
33 521 [28] Eze EC, Chenia HY, El Zowalaty ME. *Acinetobacter baumannii* biofilms: effects of
34
35 522 physicochemical factors, virulence, antibiotic resistance determinants, gene
36
37 523 regulation, and future antimicrobial treatments. *Infect Drug Resist* 2018;11:2277–
38
39 524 99. doi:10.2147/IDR.S169894.
40
41
42 525 [29] De Silva PM, Chong P, Fernando DM, Westmacott G, Kumar A. Effect of
43
44 526 Incubation Temperature on Antibiotic Resistance and Virulence Factors of
45
46 527 *Acinetobacter baumannii* ATCC 17978. *Antimicrob Agents Chemother* 2018;62.
47
48 528 doi:10.1128/AAC.01514-17.
49
50
51 529 [30] Chapartegui-González I, Lázaro-Díez M, Bravo Z, Navas J, Icardo JM, Ramos-Vivas
52
53
54
55
56
57
58
59
60

- 1
2
3 530 J. *Acinetobacter baumannii* maintains its virulence after long-time starvation.
4
5
6 531 PLoS One 2018;13:e0201961. doi:10.1371/journal.pone.0201961.
7
8 532 [31] Kaier K, Mutters NT, Frank U. Bed occupancy rates and hospital-acquired
9
10 533 infections--should beds be kept empty? Clin Microbiol Infect 2012;18:941–5.
11
12
13 534 doi:10.1111/j.1469-0691.2012.03956.x.
14
15 535 [32] Leekha S, Diekema DJ, Perencevich EN. Seasonality of staphylococcal infections.
16
17 536 Clin Microbiol Infect 2012;18:927–33. doi:10.1111/j.1469-0691.2012.03955.x.
18
19
20 537 [33] Fisman DN. Seasonality of infectious diseases. Annu Rev Public Health
21
22 538 2007;28:127–43. doi:10.1146/annurev.publhealth.28.021406.144128.
23
24
25 539 [34] Christensen AL, Lundbye-Christensen S, Dethlefsen C. Poisson regression models
26
27 540 outperform the geometrical model in estimating the peak-to-trough ratio of
28
29 541 seasonal variation: a simulation study. Comput Methods Programs Biomed
30
31 542 2011;104:333–40. doi:10.1016/j.cmpb.2011.07.016.
32
33
34 543 [35] Gerner-Smidt P. Endemic occurrence of *Acinetobacter calcoaceticus* biovar
35
36 544 anitratus in an intensive care unit. J Hosp Infect 1987;10:265–72.
37
38
39 545 [36] Iqbal Hossain M, Iqbal Kabir AK, Khan WA, Fuchs GJ. *Acinetobacter* bacteremia in
40
41 546 patients with diarrhoeal disease. Epidemiol Infect 1998;120:139–42.
42
43
44 547 [37] Morfín-Otero R, Alcántar-Curiel MD, Rocha MJ, Alpuche-Aranda CM, Santos-
45
46 548 Preciado JI, Gayosso-Vázquez C, et al. *Acinetobacter baumannii* infections in a
47
48 549 tertiary care hospital in Mexico over the past 13 years. Chemotherapy
49
50 550 2013;59:57–65. doi:10.1159/000351098.
51
52
53 551 [38] Porter KA, Rhodes J, Dejsirilert S, Henchaichon S, Siludjai D, Thamthitiwat S, et al.
54
55
56
57
58
59
60

- 1
2
3 552 Acinetobacter bacteraemia in Thailand: evidence for infections outside the
4
5
6 553 hospital setting. *Epidemiol Infect* 2014;142:1317–27.
7
8 554 doi:10.1017/S0950268813002082.
9
10
11 555 [39] Retailiau HF, Hightower AW, Dixon RE, Allen JR. *Acinetobacter calcoaceticus*: a
12
13 556 nosocomial pathogen with an unusual seasonal pattern. *J Infect Dis*
14
15 557 1979;139:371–5.
16
17
18 558 [40] Seifert H, Boullion B, Schulze A, Pulverer G. Plasmid DNA profiles of *Acinetobacter*
19
20 559 *baumannii*: clinical application in a complex endemic setting. *Infect Control Hosp*
21
22 560 *Epidemiol* 1994;15:520–8.
23
24
25 561 [41] Smego RA. Endemic nosocomial *Acinetobacter calcoaceticus* bacteremia. Clinical
26
27 562 significance, treatment, and prognosis. *Arch Intern Med* 1985;145:2174–9.
28
29
30 563 doi:10.1001/archinte.1985.00360120042006.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table I Characteristics of studies included in the review

Study	Location	Data source	Design*	Data Collection	Duration (mm/yyyy)	Follow-up (months)	No. of cases**	Seasonality objective	Method	Quality rating (%) §
Caldeira et al, 2015 [12]	Sao Paulo, Brazil	1 teaching hospital (450 beds)	Case-series	Retr.	01/2005 - 12/2010	72	177	Primary	Comp.	82
Christie et al, 1995 [26]	Connecticut , USA	1 tertiary-care hospital (770 beds)	Case-series	Pros.	01/1990 - 12/1992	36	320	Primary	Comp.	82
da Silveira et al, 2018 [8]	Sao Paulo, Brazil	1 teaching hospital (335 beds)	Case-series	Retr.	01/2006 - 12/2017	144	1207	Primary	GLM/TS	91
Davis et al, 2014 [18]	Darwin , Australia	1 tertiary referral hospital (350 beds)	Case-series	Pros.	01/1997 - 12/2012	192	41	Secondary	Gmodel	82
Eber et al, 2011 [19]	All USA	The Surveillance Network, 132 hospitals	Cohort	Pros.	01/1999 - 09/2006	93	7618	Primary	GLM/TS	100
Fillaux et al, 2006 [27]	Toulouse, France	1 university hospital (1000 beds)	Case-series	Retr.	01/2000 - 12/2003	48	791	Secondary	Comp.	73
Fortaleza et al, 2014 [13]	Sao Paulo, Brazil	1 teaching hospital (450 beds)	Case-series	Retr.	01/2005 - 12/2010	72	177	Primary	GLM/TS	91
Fukuta et al, 2012 [7]	Pittsburg, USA	1 university hospital	Case-series	Retr.	05/2000 - 04/2011	132	1476	Primary	Comp.	73
Gales et al, 2001 [17]	Canada, USA, Argentina, Chile, Colombia, Mexico, Brazil, Venezuela	46 sentinel hospitals (28 in the USA, 8 in Canada, 10 in Latin America)	Case-series	Pros.	01/1997 - 12/1999	36	261	Primary	Graph	73
Gerner-Smidt, 1987 [35]	Odense, Denmark	1 ICU (12 beds)	Cohort	Retr.	01/1984 - 12/1985	24	111	Secondary	Comp.	73
Iqbal Hossain et al, 1998 [36]	Dhaka, Bangladesh	International Centre for Diarrhoeal Disease Research	Cohort	Retr.	01/1994 - 12/1994	12	138	Secondary	Comp.	45
Kim et al, 2018 [15]	Gyeonggido, Korea	1 community hospital (742 beds)	Case-series	Retr.	01/2006 - 12/2015	120	3520	Primary	Comp.	82
Kolonitsiou et al, 2017 [14]	Patra, Greece	1 university hospital (770 beds)	Cohort	Retr.	01/2011 - 12/2013	36	151	Primary	Comp.	73
Lastoria et al, 2014 [23]	Sao Paulo, Brazil	1 teaching hospital (450 beds),	Cohort	Retr.	01/2005 - 12/2010	72	na	Secondary	Graph	55
McDonald et al, 1999 [25]	All USA	National Nosocomial Infections Surveillance	Cohort	Pros.	01/1987 - 12/1996	120	3447	Primary	Comp.	82

		System, ICU patients in 253 hospitals								
Morfin-Otero et al, 2013 [37]	Guadalajara, Mexico	1 tertiary care teaching hospital (1,000 beds)	Case-series	Retr.	01/1999 - 12/2011	156	3680	Secondary	Graph	73
Papadimitriou-Olivgeris et al, 2017 [24]	Patra, Greece	1 university hospital, ICU (13 beds)	Cohort	Retr.	01/2010 - 12/2015	72	129	Secondary	Graph	73
Perencevich et al, 2008 [20]	Maryland, USA	1 tertiary care hospital (669 beds)	Cohort	Pros.	01/1998 - 12/2005	96	1444	Primary	GLM/TS	100
Porter et al, 2013 [38]	Nakhon Phanom & Sa Kaeo, Thailand	20 hospitals	Case-series	Pros.	05/2005 - 12/2008	44	72	Secondary	Graph	64
Retailliau et al, 1979 [39]	All USA	National Nosocomial Infections System, 81 hospitals	Case-series	Pros.	07/1974	54	1372	Primary	Graph	91
Rodrigues et al, 2019 [21]	Sao Paulo, Brazil	1 teaching hospital (450 beds)	Case-series	Retr.	07/2012	48	116	Primary	Comp.	91
Schwab et al, 2014 [22]	All Germany	SARI Surveillance System, 73 ICUs in 41 hospitals	Cohort	Pros.	01/2001	144	3067	Primary	Comp.	100
Seifert et al, 1994 [40]	Cologne, Germany	4 ICUs in a university hospital (800 beds)	Case-series	Pros.	01/1991	12	189	Secondary	Graph	64
Siau et al, 1996 [16]	Hong-Kong	1 tertiary care hospital (1350 beds)	Case-series	Retr.	01/1990	59	7475	Primary	Graph	91
Smego, 1985 [41]	West Virginia, USA	1 university hospital (450 beds)	Case-series	Retr.	01/1979	60	27	Secondary	Graph	73

ICU, intensive care unit; Retr., retrospective; Pros., prospective; Comp., direct comparison of incidence frequencies between discrete calendar periods;

Graph, graphical inspections of incidence frequency over time; Gmodel, geometrical model; GLM/TS, generalised linear model or time series regression.

* With regard to assessing seasonality, longitudinal studies with strictly-outcome based sampling (i.e. only patients infected or colonized by *Acinetobacter*) were labelled "case series". Longitudinal studies that sampled from the pool of hospitalized patients were labelled "cohort" studies.

** Overall number of infections or colonizations recorded during the study period.

§ Based on the percentage of fulfilled applicable criteria in accordance with the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [10]

Table II Monthly incidence of *Acinetobacter* infection (27 data series) retrieved from 21 studies

Study	Incidence measure	Sub-group	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Peak Season [§]
Christie et al, 1995 [26]	Avg monthly proportion (%) of inpatients with BSI by <i>A. baumannii</i> *	-	6.5	6.5	4.7	4.7	4.7	14.6	14.6	14.6	7.7	7.7	7.7	6.5	Summer
Davis et al, 2014 [18]	Cumulative monthly count of community-onset pneumonias caused by <i>Acinetobacter</i> spp.*	-	6	3	5	3	2	2	0	0	3	4	2	11	Summer
Eber et al, 2011 [19]	Avg monthly number of BSIs by <i>Acinetobacter</i> spp.*	-	0.5	0.46	0.51	0.49	0.62	0.64	0.79	0.675	0.78	0.725	0.62	0.57	Autumn
Fillaux et al, 2006 [27]	Avg monthly proportion (%) of <i>A. baumannii</i> clinical isolates	-	10.7	7.2	5.5	4.7	6.4	6.0	8.5	11.8	11.3	10.2	9.6	8.0	Autumn
Fukuta et al, 2012 [7]	Cumulative monthly count of <i>Acinetobacter</i> spp isolates*	Not MDR MDR	32 108	26 62	30 69	36 64	39 64	47 40	97 62	121 55	100 49	63 64	47 63	54 84	Summer Winter
Gales et al, 2001 [17]	Cumulative monthly count of BSIs due to <i>Acinetobacter</i> spp.*	Canada & USA Latin America	12 11	11 13	1 6	8 9	5 6	12 11	15 15	8 17	11 7	20 16	9 13	13 11	Autumn Winter
Gerner-Smidt, 1987 [35]	Avg quarterly proportion (%) of <i>A. calcoaceticus</i> colonizations over all ICU admissions	-	6.4	6.4	6.4	6.2	6.2	6.2	7.0	7.0	7.0	5.4	5.4	5.4	Summer
Iqbal Hossain et al, 1998 [36]	Monthly proportion (%) of inpatients with BSI by <i>Acinetobacter</i> spp.	-	2.8	2.8	2.8	2.3	2.3	2.3	2.4	2.4	2.4	1.3	1.3	1.3	Spring
Kim et al, 2018 [15]	Avg monthly proportion of <i>Acinetobacter</i> spp. clinical isolates per 1,000 patients	COI HAI	9.9 10.7	11.2 7.9	9.1 9	11.3 8.9	10.5 8.9	11 8.4	12.2 8.7	18.1 9.2	14.6 11.1	9.9 9	10.6 8.5	7.6 12.6	Summer Winter
Lastoria et al, 2014 [23]	Avg monthly rate of BSI by <i>A. baumannii</i> per 10,000 patient-days *	-	2.40	2.61	1.44	2.19	3.24	5.08	1.79	1.92	2.40	2.03	2.60	1.75	Winter
McDonald et al, 1999 [25]	Avg monthly rate of infections per 10,000 patient-days in ICU*	<i>A. baumannii</i> <i>Acinetobacter</i> spp.	4.15 0.53	4.68 0.29	3.63 0.86	3.71 1.17	3.22 1.13	4.77 1.12	6.09 1.60	7.08 1.29	6.29 1.51	5.48 1.19	4.74 1.06	4.03 0.94	Summer Summer
Morfin-Otero et al, 2013 [37]	Avg. monthly count of <i>A. baumannii</i> clinical isolates*	-	246.3	246.3	246.3	340.7	340.7	340.7	341.3	341.3	341.3	298.3	298.3	298.3	Summer

Papadimitriou-Olivgeris et al, 2017 [24]	Avg monthly rate of BSI by <i>A. baumannii</i> per 1,000 ICU-days*	-	7.74	3.54	3.63	5.13	5.6	8.73	2.35	9.26	3.77	4.91	3.14	3.51	Summer
Perencevich et al, 2008 [20]	Cumulative monthly count of <i>A. baumannii</i> clinical isolates*	-	114	100	108	112	111	131	128	162	128	127	114	111	Summer
Porter et al, 2013 [38]	Cumulative monthly count of patients with BSI by <i>Acinetobacter</i> spp.*	HAI COI	5 0	3 1	7 3	4 4	2 0	4 8	4 5	5 3	3 4	1 0	2 1	0 3	Spring Spring
Retailiau et al, 1979 [39]	Avg. monthly count of infections by <i>A. calcoaceticus</i> *	-	27.5	23.9	23.6	28.4	31.1	32.5	46.9	49.9	37.6	37.4	26.4	22.6	Summer
Rodrigues et al, 2019 [21]	Avg monthly count of hospital-acquired BSIs by <i>A. baumannii</i>	-	10.7	10.7	10.7	10.7	10.7	7.0	7.0	7.0	10.3	10.3	10.3	10.7	Summer
Schwab et al, 2014 [22]	Avg monthly rate of <i>A. baumannii</i> clinical isolates per 1,000 patient-days in ICU*	-	1.05	1.39	1.44	1.36	1.40	1.61	2.07	1.76	1.43	1.49	1.25	1.15	Summer
Seifert et al, 1994 [40]	Monthly count of ICU patients with clinical culture positive for <i>A. baumannii</i> *	-	24	14	14	11	19	22	13	16	15	16	13	12	Summer
Siau et al, 1996 [16]	Cumulative monthly count of <i>Acinetobacter</i> clinical isolates *	ICU patients Ward patients	194 518	176 491	172 567	155 594	172 614	166 657	230 810	186 792	197 757	209 745	300 685	178 519	Autumn Summer
Smego, 1985 [41]	Cumulative monthly count of patients with blood culture positive for <i>A. calcoaceticus</i> *	-	3	1	3	2	0	4	7	1	3	1	1	1	Summer

Avg, average; BSI, bloodstream infection; ICU, intensive-care unit; MDR, multi-drug resistant; COI, community onset infection; HAI, hospital-acquired infection.

* Data extracted from graph(s).


§ Peak season was defined as the season for which the sum of monthly incidence data was highest. Season are reported in accordance to hemisphere (e.g., summer is defined as June–August in the northern hemisphere and December–February in the southern hemisphere).

FIGURE CAPTIONS









Figure 1. PRISMA flow diagram of the literature search conducted on 23rd October 2018 to identify longitudinal epidemiological studies investigating seasonal variation in the incidence of infection caused by *Acinetobacter* species in hospitalized patients.

Figure 2. Graphical assessment of monthly incidence of *Acinetobacter* infection in hospitalized patients using 27 data series retrieved from 21 studies. Data were adjusted by six months in data series from the southern hemisphere (i.e. January = M7). Panel (a) weighting schemes were based on follow-up time (weight-1), overall number of infections (weight-2), composite product of follow-up time and number of infections (weight-3) and overall quality rating of each study (weight-4). The composite weight-3 was used in panels (b)-(h). n, number of data series; BSI, bloodstream infection; PNU, pneumonia; COI/CAI, community-onset or community-acquired infection; HAI, hospital-acquired infection; MIX, not distinguishing between different types.

Figure 1.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Supplementary Data

Appendix A. Search strategy

Database: **EMBASE**

Host: **OVID**

Data Parameters: **<1974 to 2018 October 23>**

Date Searched: **OCTOBER 23rd, 2018**

Hits: **177**

#	Searches	Results
1	season*.mp. [mp=tx, bt, ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq]	193001
2	Acinetobacter baumannii.mp. [mp=tx, bt, ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq]	13453
3	"Acinetobacter".mp. [mp=tx, bt, ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq]	26443
4	Acinetobacter infections.mp. [mp=tx, bt, ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq]	310
5	seasonal pattern.mp. [mp=tx, bt, ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq]	2941
6	1 or 5 (193001)	193001
7	2 or 3 or 4	26443
8	6 and 7	177

Database: **Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R)**

Host: **OVID**

Data Parameters: **<1946 to October 23, 2018>**

Date Searched: **OCTOBER 23rd, 2018**

Hits: **127**

#	Searches	Results
1	Acinetobacter baumannii.mp. or *Acinetobacter/ or *Acinetobacter baumannii/ or *Acinetobacter Infections/	10108
2	"Acinetobacter".mp. or ACINETOBACTER BAUMANNII/ or ACINETOBACTER/ or ACINETOBACTER CALCOACETICUS/ or ACINETOBACTER INFECTIONS/	15974
3	seasons.mp. or SEASONS/	112894
4	SEASONS/ or season*.mp. (189938
5	Seasons/ or seasonal pattern.mp.	98375
6	1 or 2	15974
7	3 or 4 or 5	189938
8	6 and 7	127

Database: **SCOPUS**

Data Parameters: **<from inception to October 23, 2018>**

Date Searched: **OCTOBER 23rd, 2018**

Hits: **64**

#	Searches	Results
	(TITLE-ABS-KEY((ACINETOBACTER AND BAUMANNII) OR (ACINETOBACTER) OR (ACINETOBACTER AND INFECTIONS)) OR TITLE-ABS-KEY (*ACINETOBACTER*)) AND (TITLE-ABS-KEY (SEASONS) OR (*SEASON)) AND NOT INDEX (MEDLINE) AND (LIMIT-TO (LANGUAGE,"ENGLISH")) AND (LIMIT-TO (EXACTKEYWORD,"ACINETOBACTER")) OR LIMIT-TO (EXACTKEYWORD,"HUMAN") OR LIMIT-TO (EXACTKEYWORD,"HUMANS") OR LIMIT-TO (EXACTKEYWORD,"ACINETOBACTER BAUMANNII"))	64

Database: **WEB OF SCIENCE**

Data Parameters: <from inception to October 23, 2018>

Date Searched: **OCTOBER 23rd, 2018**

Hits: **55**

#	Searches	Results
1	TI=(ACINETOBACTER BAUMANNII/OR ACINETOBACTER/ OR ACINETOBACTER INFECTIONS) Timespan=All years Search language=English	14,779
2	TS=(ACINETOBACTER) Timespan=All years Search language=English	38,321
3	TI=(SEASON*/OR SEASONAL PATTERN) Timespan=All years Search language=English	193,548
4	#2 OR#1 Timespan=All years Search language=English	38,321
5	#4 AND #3 Timespan=All years Search language=English	55

Appendix B. Excluded studies with reasons

Study identification	Title	DOI	Reason for exclusion
Adams D et al., 2011	Investigation and management of an <i>A. Baumannii</i> outbreak in ICU	10.12968/bjon.2011.20.3.140	Outbreak report
Al Masoudi et al., 2013	Incidence and prevalence of <i>Acinetobacter baumannii</i> in king fahd general hospital, Saudi Arabia	ISSN:1097-8135	Less than 12 months follow-up
Brahmi et al., 2007	Epidemiology and risk factors for colonization and infection by <i>Acinetobacter baumannii</i> in an ICU in Tunisia, where this pathogen is endemic	10.1007/s10156-007-0557-0	Outbreak report
Chu YW et al	Skin carriage of <i>Acinetobacters</i> in Hong Kong	jcm.asm.org/content/37/9/2962	Not reporting the incidence of <i>Acinetobacter</i> spp. infection or colonization.
Freeman et al., 2009	Emerging evidence for seasonality of gram-negative bacterial infections	10.1086/597506	Commentary article. Not a longitudinal observational study. Not reporting the incidence of <i>Acinetobacter</i> spp. infection or colonization.
Herruzo et al., 2004	Two consecutive outbreaks of <i>Acinetobacter baumannii</i> 1-a in a burn Intensive Care Unit for adults	10.1016/j.burns.2004.01.008	Outbreak report
Hurley et al., 2016	Worldwide variation in incidence of <i>Acinetobacter</i> associated ventilator associated pneumonia: a meta-regression.	10.1186/s12879-016-1921-4	Not a longitudinal observational study. Not reporting the incidence of <i>Acinetobacter</i> spp. infection or colonization.
Mc Donald et al., 1998	Outbreak of <i>Acinetobacter</i> spp. bloodstream infections in a nursery associated with contaminated aerosols and air conditioners.	10.1097/00006454-199808000-00011	Outbreak report
Munoz-Price et al., 2008	<i>Acinetobacter</i> infection	10.1056/NEJMra070741	Literature review. Not a longitudinal observational study
Ramphal et al	<i>Acinetobacter calcoaceticus</i> variety <i>anitratus</i> : An increasing nosocomial problem.	10.1097/00000441-197901000-00007	Could not retrieve full text
Schloesser et al., 1990	An Outbreak of <i>Acinetobacter calcoaceticus</i> Infection in a Neonatal Care Unit	10.1007/BF01643394	Outbreak report
Schwab et al., 2009	Summer season in the incidence of Gram-negative bacteria in ICUs	NA	Conference abstract for which the published paper has been included in the review.
Seifert et al., 1995	Nosocomial bacteremia due to <i>Acinetobacter baumannii</i> : Clinical features, epidemiology, and predictors of mortality	10.1097/00005792-199511000-00004	Not reporting the incidence of <i>Acinetobacter</i> spp. infection or colonization.

Smith et al., 1979	Seasonal incidence of <i>Acinetobacter</i> infection	10.1093/infdis/140.2.275	Commentary. Not a longitudinal observational study.
Wisplinghoff et al., 2000	Nosocomial Bloodstream Infections Caused by <i>Acinetobacter</i> Species in United States Hospitals: Clinical Features, Molecular Epidemiology, and Antimicrobial Susceptibility	10.1086/314040	Not reporting the incidence of <i>Acinetobacter</i> spp. infection or colonization.
Yallew et al., 2016	Point prevalence of hospital-acquired infections in two teaching hospitals of Amhara region in Ethiopia	10.2147/DHPS.S107344	Not longitudinal, less than 12 months follow-up
Zhang et al., 2014	Epidemiological investigation on respiratory diseases in 1300 children, in Jinan, Shandong	cma.j.issn.0254-6450.2014.11.022	Not in English language

Appendix C. Critical appraisal of the quality of reviewed studies

Critical appraisal of study quality was based on the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. We utilized 11 of 14 criteria that were applicable in the context of this review as shown in Table C1. All criteria were applied in accordance with the guidelines developed by the authors of the tool with the additional considerations and/or modifications shown in Table C1. A summary of our quality appraisal of reviewed studies is presented in Table C2. To obtain a crude sense of overall study quality, we calculated the percentage of fully fulfilled criteria for each study (i.e. percentage of “yes” responses to applicable criteria).

Table C1. Criteria in the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies and modifications in the current review

No.	Criterion	Modification or additional consideration
Q1.	Was the research question or objective in this paper clearly stated?	Assessed in relation to seasonality objective. Set to “Yes” only in studies that had a specific primary objective of assessing seasonal variation in the incidence of <i>Acinetobacter</i> infection.
Q2.	Was the study population clearly specified and defined?	Set to “Yes” in studies that included a clear statement or description of their target population irrespective of whether a summary presentation of patient demographics was presented or not. An example of a clear statement for the target population would be “Inpatients with a clinical culture positive for <i>A. baumannii</i> collected after day 3 of hospital admission.”
Q3.	Was the participation rate of eligible persons at least 50%?	Set to “No” only when there were legitimate reasons to expect that the study methodology or implementation would lead to exclusion of a substantial proportion of eligible patients in the target population.
Q4.	Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	-

Q5.	Was a sample size justification, power description, or variance and effect estimates provided?	Set to "Yes" if any of the following applied: (a) clear justification of sample size in accordance with the tool guidelines, or (b) large effective sample size of at least 10 cases per month of follow up, or (c) reported low p-values for differences or trends (e.g. in Edward's test for seasonality).
Q6.	For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	The exposure of interest was taken to be calendar season or any other discrete time period. The outcome of interest was the occurrence of <i>Acinetobacter</i> infection. All studies examined the association between exposure and outcome longitudinally. Therefore, Criterion Q6 was not applicable in this review.
Q7.	Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	Eligibility criteria required at least 12 months of follow-up, so that at least a single comparison between seasons could be performed. Obviously, studies with repetition over several years would be more likely to detect true seasonality. Criterion Q7 was set to "Yes" for studies having at least 2 years of follow-up (i.e. at least two repetitions).
Q8.	For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	The exposure of interest was taken to be calendar season or any other discrete time period. Therefore, Criterion Q8 was not applicable in this review.
Q9.	Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	-
Q10.	Was the exposure(s) assessed more than once over time?	Set to "No" for studies having less than 1 year of follow-up and for those that performed 2-group comparisons of incidence data (e.g. summer v. winter). It was set to "Yes" when the data were examined longitudinally for at least 2 years of follow-up and a formal assessment of seasonality was included.
Q11.	Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	-
Q12.	Were the outcome assessors blinded to the exposure status of participants?	Q12 was not applicable in this review.
Q13.	Was loss to follow-up after baseline 20% or less?	None of the studies reported loss to follow-up. Criterion Q13 was set to "No" only when there were legitimate reasons to expect that the study methodology or implementation would lead to substantial losses to follow-up.
Q14.	Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	This criterion was set to "Yes" for studies that utilised regression models to adjust for variation in climate parameters and/or other risk factors.

Table C2. Summary of the critical appraisal of the quality of reviewed studies

Study	Q1	Q2	Q3	Q4	Q5	Q7	Q9	Q10	Q11	Q13	Q14	"Y" count	"Y" percent (%)
Caldeira et al, 2015	Y	Y	Y	Y	N	Y	Y	N	Y	Y	Y	9	82
Christie et al, 1995	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	N	9	82
da Silveira et al, 2018	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	10	91
Davis et al, 2014	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	9	82
Eber et al, 2011	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	11	100
Fillaux et al, 2006	N	Y	Y	Y	Y	Y	Y	N	Y	Y	N	8	73
Fortaleza et al, 2014	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	10	91
Fukuta et al, 2012	Y	Y	Y	Y	N	Y	Y	N	Y	Y	N	8	73
Gales et al, 2001	Y	Y	Y	Y	N	Y	Y	N	Y	Y	N	8	73
Gerner-Smidt, 1987	N	Y	Y	Y	N	Y	Y	Y	Y	Y	N	8	73
Iqbal Hossain et al, 1998	N	CD	CD	Y	Y	N	Y	N	Y	Y	N	5	45
Kim et al, 2018	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	N	9	82
Kolonitsiou et al, 2017	Y	N	Y	Y	N	Y	Y	Y	Y	Y	N	8	73
Lastoria et al, 2014	N	Y	Y	Y	N	Y	N	N	Y	Y	N	6	55
McDonald et al, 1999	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	N	9	82
Morfin-Otero et al, 2013	N	Y	Y	Y	Y	Y	Y	N	Y	Y	N	8	73
Papadimitriou-Olivgeris et al, 2017	N	Y	Y	Y	N	Y	Y	Y	Y	Y	N	8	73
Perencevich et al, 2008	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	11	100
Porter et al, 2013	N	Y	Y	Y	N	Y	Y	N	Y	Y	N	7	64
Retailiau et al, 1979	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	10	91
Rodrigues et al, 2019	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	10	91
Schwab et al, 2014	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	11	100
Seifert et al, 1994	N	Y	Y	Y	Y	N	Y	N	Y	Y	N	7	64
Siau et al, 1996	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	10	91
Smego, 1985	N	Y	Y	Y	N	Y	Y	Y	Y	Y	N	8	73

Y, Yes; N, No; CD, cannot determine.



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4 (lines 72-76)
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5 (lines 81-83)
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5, 6 (lines 97-118)
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5 (lines 85-94)
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5 (lines 85-94) + Appendix A
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5, 6 (lines 97-118)
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6,7 (lines 120-131) + Appendices B, C
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6,7 (lines 120-131) + Appendix C
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7, 8 (lines 141-151)
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7 (lines 134-145)



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7 (lines 134-145)
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8 (lines 147-157)
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	NA
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8 (lines 162-163), + Figure 1 + Appendix B
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8,9 (lines 164-182) + Table I
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9,10 (lines 184-196) + Appendix C
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	(a) Tables I and II, Figure 2.
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-11 + Figure 2 (descriptive analysis of data pooled across subgroups)
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9, 10 + Appendix C, Figure 2
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	NA
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14 – 17
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	18-19
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	19-20



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	20

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

For Peer Review